Skip to content


Journal for ImmunoTherapy of Cancer

Call for papers

Journal for ImmunoTherapy of Cancer is proud to launch three thematic series on the topics of Emerging Immunotherapeutic Agents, New Regulatory Approvals in Cancer Immunotherapy, and Challenges in Clinical Management. Submissions are welcome for consideration through March 2, 2018. 

Learn more here.              

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. 

Read more, explore our article types and sections, and submit your manuscript.


  1. Content type: Case report


    Authors: Amrita Padda, Elena Schiopu, Justin Sovich, Vincent Ma, Ajjai Alva and Leslie Fecher

View all articles
View all articles

Society affiliation

Journal for Immunotherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). SITC is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2018. Please contact  for further information.

Learn more about SITC’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy at SITC Cancer Immunotherapy CONNECT.


Pedro Romero, Ludwig Center for Cancer Research

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Latest Tweets


2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    1157.0 Usage Factor

    Social Media Impact
    114 mentions